Background -Knowing the extent of the systemic effects of a new P2 agonist relative to an established drug is important for the prediction and interpretation of side effects. A recent study in which the effect of cumulative doses of salbutamol was compared with single doses of salmeterol suggested that, weight for weight, salmeterol may be up to 10 times more potent than salbutamol. This current study was designed to investigate further the dose equivalence of salmeterol and salbutamol.
Abstract
Background -Knowing the extent of the systemic effects of a new P2 agonist relative to an established drug is important for the prediction and interpretation of side effects. A recent study in which the effect of cumulative doses of salbutamol was compared with single doses of salmeterol suggested that, weight for weight, salmeterol may be up to 10 times more potent than salbutamol. This current study was designed to investigate further the dose equivalence of salmeterol and salbutamol.
Methods -Twelve patients with mild asthma inhaled cumulative doses of placebo, salmeterol 25, 50, 100, and 200pg, and salbutamol 100, 500, 1000, and 1000 pg on separate days at hourly intervals in a randomised double blind crossover study. Changes in forced expiratory volume in one second (FEVy), heart rate, plasma potassium concentration, systolic and diastolic blood pressure were measured. Dose equivalence was determined as the dose ratio of salmeterol to salbutamol for the 50% maximum reponse to salbutamol. Results -No important changes occurred in any measurements following placebo. Salmeterol and salbutamol caused a near maximum increase in FEV, following the first dose so the dose equivalence for the airway effects could not be estimated. Heart rate increased and plasma potassium concentration and diastolic blood pressure decreased in a dose dependent manner following salmeterol and salbutamol, with median dose equivalences for salmeterol compared with salbutamol of 17-7, 7-8, and 7-6, respectively. Conclusions -These results confirm that the systemic activity of salmeterol compared with salbutamol is higher than would be expected from in vitro data, particularly for heart rate. Whether this is because of the relatively high dose of salmeterol used or pharmacokinetic differences between the two drugs is uncertain. (Thorax 1994; 49:771-774) Salmeterol given in a dose of 50 jg twice daily provides more effective control of asthma symptoms than salbutamol in doses of 200 jig and 400 gg four times daily in short term studies. ' FEV, was measured by a dry bellows spirometer (Vitalograph, Buckingham, UK) with the subject sitting, taking the best of two successive measurements within 100 ml. Heart rate was measured over 60 seconds by palpation ox-the radial pulse. Venous blood samples (10 ml) were taken from a cannula in the forearm (Butterfly 21), placed in a lithium heparin bottle, and centrifuged within 20 minutes of sampling at 3000 revs/min for 15 minutes. Plasma potassium concentration was measured by flame photometry (Olympus AU5000, Olympus Optical Company, Eastleigh, UK).
Subjects were studied at the same time of day on three occasions separated by at least seven days. Inhaled 12 agonists and caffeine containing drinks were withheld for 12 hours before each visit. Following a 30 minute rest baseline measurements of heart rate, blood pressure, and FEV1 were made, and blood was taken for plasma potassium assay. Subjects were then given increasing doses of placebo, salmeterol (25, 50, 100, and 200pg) or salbutamol (100, 500, 1000, and 1000 jg) by metered dose inhaler at hourly intervals according to a randomised, double blind, double dummy, crossover design. Doses of salmeterol, salbutamol, and placebo other than the first dose were administered using a large volume spacing device (Volumatic). At each visit two identical metered dose inhalers (active or placebo) were used, patients receiving one, two, four, and eight puffs from one inhaler and one, five, 10, and 10 puffs from the other. The first inhaler was active on the salmeterol day giving doses of 25, 50, 100, and 200 rg, and the second inhaler was active on the salbutamol day giving doses of 100, 500, 1000, and 1000 gg. Two, four, or five puffs were activitated into the spacer before two inhalations; for higher doses this was repeated on a second occasion. Patients held their breath for 10 seconds after each inhalation. Each drug dose was administered over a period of three minutes. Further measurements were taken at 15 and 60 minutes after each dose in the same order as at baseline, and a final set of measurements was taken 120 minutes after the last dose of drug. The maximum change after each dose was used in the analysis. The study was stopped if symptoms became troublesome or if the heart rate rose above 140 beats/minute. Patients Individual values for dose equivalence were calculated by plotting the response to each dose of salmeterol and salbutamol on a log doseresponse curve and drawing a line of regression through the linear part of the curve taking the last three readings. Dose equivalence was measured at 50% of the maximal effect seen with salbutamol by comparing the dose of salbutamol and salmeterol required to achieve this effect. Individual dose equivalences were not normally distributed and are described as median and interquartile range.
Since the earlier doses of salbutamol may not have been effective at the time of administration of the final dose because of its shorter duration of action, we also calculated a minimum dose equivalence assuming that at the time of each drug administration only 50% of the preceding dose was active. This gave a cumulative dose range of 100, 500, 1250, and 1500 jig for salbutamol.
The log dose-responses for the two drugs were tested by analysis of variance to determine whether they deviated from parallelism. '3 The generalised interactive modelling (GLIM) statistical package was used for statistical analysis.
Results
All patients completed all three dose-response studies. There were no significant differences in baseline measurements of FEV,, heart rate, plasma potassium concentration, and systolic and diastolic blood pressure (table 1) , and no important changes in any of these measurements were seen after placebo (table 2). None of the log dose-reponses for the two drugs was found to deviate from parallelism (all p > 0 05).
CHANGE IN FEVy
There was a near maximal increase in FEVI following the first dose of both salmeterol (0-42 1) and salbutamol (041 1) and progressively smaller increases after further doses ( fig  1) . The maximum increase was 0-621 and 0-571 respectively (table 2). CHANGE IN HEART RATE, PLASMA POTASSIUM, AND BLOOD PRESSURE Salmeterol and salbutamol caused a largely dose dependent increase in heart rate and fall in plasma potassium concentration and diastolic blood pressure (fig 1) . The median dose equivalence for salmeterol compared with salbutamol was 17 7 (interquartile range 9-2-21-8) for heart rate, 7 8 (interquartile range 3-7-10 7) for Time (min) plasma potassium concentration, and 7-6 (interquartile range 2-7-19-4) for diastolic blood pressure. Systolic blood pressure did not change significantly after cumulative doses of either drug. The minimum dose equivalence for salmeterol compared with salbutamol calculated from each dose administered and 50% of the preceding dose was 12-2 for heart rate, 6-8 for plasma potassium concentration, and 7-7 for diastolic blood pressure.
After the last dose of salbutamol the maximal effect on heart rate, FEVI, plasma potassium concentration, and diastolic blood pressure was seen after 20 minutes (fig 2) . One criticism raised of our previous study was that only one measurement was made after each dose of drug and that the maximum drug effect may have been missed. In the present study measurements were made 20 and 60 minutes after each dose with a further measurement 120 minutes after the last dose. After the final dose of salmeterol there was little difference in the effects seen at 60 and 120 T minutes. With salbutamol the maximum effect was seen at 20 minutes following the final dose I with a gradual decrease in effect at 60 and 120 minutes. These results suggest that we had measured the maximum effects of both drugs 20 after each dose. The responses to both salmeterol and salbutamol in our study are very 773 jF group.bmj.com on June 22, 2017 -Published by http://thorax.bmj.com/ Downloaded from similar to those seen in other studies. Maconochie et al found a similar increase in heart rate (16 beats/min) and fall in plasma potassium concentration (0-45 mmol/l) following a single 400 1tg dose of salmeterol in normal subjects'4 to that seen in our study with cumulative doses (total dose 375 fig). The magnitude of change for all measurements following cumulative doses of salbutamol was similar to that seen in our previous studies.9 15 We were unable to estimate the dose equivalence of salbutamol and salmeterol for the airway effects since a near maximum response was achieved with the lowest dose of both drugs. The dose equivalence for fall in plasma potassium concentration and diastolic blood pressure was 7-8, which agrees closely with estimates from our previous study; the dose equivalence for heart rate was greater at 17 7. It is possible that the dose equivalence is an overestimate since the doses of salbutamol may not be truly cumulative because of its shorter duration of action. Any effect this might have on our estimate of dose equivalence would have been small -for example, assuming the final dose of salbutamol to be 1500 g.g (50% of the penultimate dose and the final dose) rather than 2600 gig (the total dose) would reduce the dose equivalence for heart rate from 17 7 to 12 2.
The greater systemic effects of salmeterol relative to salbutamol in vivo may be due to increased systemic bioavailability, increased dose, or differences in ,B receptor selectivity.
The dose equivalence for systemic P2 mediated effects, such as the fall in serum potassium levels, are higher than would be expected from studies in vitro where salmeterol is approximately five times more potent than salbutamol on a weight for weight basis. 16 17 This suggests that the systemic dose for salmeterol is high compared with salbutamol. Whether this is because of the high dose administered or differences in systemic availability is difficult to determine without knowing the relative effect of the two drugs on the airways. Systemic effects of salbutamol are largely due to the inhaled rather than the swallowed portion of the drug,'8 partly because it undergoes first pass metabolism. '9 The fate of the swallowed portion of salmeterol is unknown and it is possible that its greater systemic effects are due to decreased first pass metabolism. Differences in oropharyngeal or lung deposition of the two drugs are unlikely to account for our findings as both drugs were administered using the same delivery system. Dose equivalence for heart rate was higher than that of plasma potassium concentration. This finding was receptors.
In conclusion we have shown that, for systemic effects, salmeterol is 7-17 times more potent than salbutamol. Further work is needed to determine whether this is a result of pharmacokinetic differences or differences in dose. Whatever the mechanism, the difference between the two in their propensity to increase heart rate may be relevant to the concerns about mortality with salmeterol compared with salbutamol which have been raised in the recent post-marketing surveillance study.23
We thank Mr A Wisniewski and Mrs J Williams for help with the study and Mrs S Pacey for randomisation and coding of the drugs.
